Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Brigham and Women's Hospital
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06438146CT.gov LIROH - Liraglutide for Obesity in HIV | — | Unknown | — | — | — |
NCT02743598CT.gov Liraglutide for HIV-associated Neurocognitive Disorder | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · HIV Infectious Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Liraglutide (this asset) | Brigham and Women's Hospital | Approved | BB · 65 |
| Raltegravir | Helsinki University Central Hospital | P4 | A |
| Retrovir | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | P4 | BBB |
| Efavirenz | The Cleveland Clinic | P4 | BBB |
| Abacavir | Germans Trias i Pujol Hospital | P4 | BBB |
| Dolutegravir | Instituto Mexicano del Seguro Social | P4 | BBB |
| Nevirapine Anhydrous | Germans Trias i Pujol Hospital | P4 | BBB |
| NORVIR | Giovanni Di Perri | P4 | BBB |
| Pravastatin | Ospedale di Circolo - Fondazione Macchi | P4 | BBB |
+38 more in the HIV Infectious Disease cohort
Other indications for Liraglutide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Disease | — | P4 | A · 84 |
| Type 1 Diabetes Mellitus | — | P4 | BBB · 79 |
| Type 2 Diabetes Mellitus | — | P4 | BBB · 79 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Liraglutide in HIV Infectious Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/liraglutide-hiv-infectious-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →